Form 4: Tela Bio Director Federica F. O'Brien Reports Acquisition of Stock and Stock Options

Director Federica F. O'Brien reports acquiring common stock and stock options in Tela Bio, Inc.

Summary

• On June 4, 2024, Federica F. O'Brien, a director of Tela Bio, Inc., acquired 4,250 shares of common stock and stock options for 6,200 shares.
• The common stock was acquired at a price of $0.
• Following the transaction, O'Brien directly owns 10,520 shares of common stock.
• The stock options have an exercise price of $5.71 and expire on June 4, 2034.
• The restricted stock units and options vest on the earlier of June 4, 2025, the next annual meeting of stockholders, or a Change in Control, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director is generally a positive sign, but the filing itself is a routine disclosure.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units and options is contingent on continued service and could be accelerated by a change in control.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates